The malaria parasite Plasmodium depends on the tight control of cysteineprotease activity throughout its life cycle. Recently, the characterization of a new class of potent inhibitors of cysteine proteases (ICPs) secreted by Plasmodium has been reported. Here, the recombinant production, purification and crystallization of the inhibitory C-terminal domain of ICP from P. berghei in complex with the P. falciparum haemoglobinase falcipain-2 is described. The 1:1 complex was crystallized in space group P4 3 , with unit-cell parameters a = b = 71.15, c = 120.09 Å . A complete diffraction data set was collected to a resolution of 2.6 Å .
Introduction
Facilitating uptake and egress from host cells, activation of proenzymes and haemoglobin degradation, cysteine proteases have important functions during most stages of the complex life cycle of the malaria parasite Plasmodium (Coppens et al., 2010; Drew et al., 2008; Hogg et al., 2006; Rosenthal, 2004; Sturm et al., 2006) . Especially well characterized is the role of Plasmodium cysteine proteases in haemoglobin hydrolysis, which takes place during the blood stage after uptake of parasites into erythrocytes. Previously, we and others have determined the structure of the papain-type protease falcipain-2 (FP-2), which is critical for intraerythrocytic haemoglobin breakdown (Wang et al., 2006; Hogg et al., 2006; Kerr et al., 2009) . Plasmodium tightly controls the proteolytic activity of FPs and other endogenous cysteine proteases, and stage-specific activation is vital for survival and successful propagation of the parasite within its host. It has been suggested that in addition to its own proteases, Plasmodium regulates the activity of host-cell cysteine proteases , which mediate apoptosis and represent an important part of the host's immune system through presentation of parasite-derived material by MHC molecules. Many organisms employ specific protease inhibitors to shut down proteases at times when proteolytic activity might be harmful.
The genomes of Plasmodium species encode an endogenous protease inhibitor belonging to the recently defined family of inhibitors of cysteine proteases (ICPs; MEROPS family I42; Rawlings et al., 2008) . In P. falciparum, ICP has been designated as falstatin . ICP proteins have also been identified in other eukaryotes, bacteria and archaea (Rigden et al., 2002; Sanderson et al., 2003) . While chagasin, a member of the I42 family, regulates the activity of the endogenous protease cruzipain in Trypanosoma cruzi (Monteiro et al., 2001) , the target proteases for other ICPs are largely unknown (Sanderson et al., 2003) . To date, only two members of the I42 family have been structurally characterized. The structures of chagasin and ICP from Leishmania mexicana have been determined by X-ray crystallography (Figueiredo da Silva et al., 2007) and NMR (Salmon et al., 2006; Smith et al., 2006) . In addition, X-ray structures of macromolecular complexes of cysteine proteases with chagasin are available, showing that the inhibitor interacts with target proteases via a tripartite binding motif that includes loops L2, L4 and L6 (Ljunggren et al., 2007; Redzynia et al., 2008 Redzynia et al., , 2009 Wang et al., 2007) .
Plasmodium ICPs consist of a chagasin-like C-terminal part (ICP-C) and a unique nonhomologous N-terminal part (ICP-N) of unknown function which is missing in other ICP-family members. The C-terminal domain of Plasmodium ICPs acts as a potent inhibitor of FP-2 and other cysteine proteases (Hansen et al., 2011; Rennenberg et al., 2010) . However, the structure, function and target protease(s) of Plasmodium ICPs are largely unknown. Here, we report the production, purification and crystallization of ICP-C from P. berghei (PbICP-C) in complex with FP-2. The three-dimensional structure determination will enable an in-depth understanding of Plasmodium ICPs and provide detailed information on specific interactions with target proteases.
Cloning
A plasmid for the expression of PbICP-C was constructed by amplifying the DNA sequence encoding amino-acid residues 190-354 from cDNA using 5 0 -TTCATATGGGAGATGAAAAATGTGGTA-AATCA-3 0 as the forward primer and 5 0 -TTGAATTCTTATTGGA-CAGTCACGTATATAAT-3 0 as the reverse primer, including NdeI and EcoRI restriction sites (bold), respectively. The PCR product was purified and ligated into a pJC45 expression vector (Schlü ter et al., 2000) encoding an N-terminal His 10 tag. After verification of the DNA sequence, the plasmid was transformed into BL21 (DE3) competent cells harbouring a pAPlacI Q plasmid (Schlü ter et al., 2000) . The cloning of FP-2 (FP-2 Cys42Ala, a mature inactive variant of the FP-2 precursor, previously designated FPc285aM) has been described elsewhere (Hogg et al., 2006) . The complete amino-acid sequences of PbICP-C and FP-2 are given in Appendix A.
Protein production and purification and preparation of the PbICP-C-FP-2 complex
Recombinant PbICP-C was expressed at 310 K by the addition of isopropyl -d-1-thiogalactopyranoside (IPTG; final concentration 1 mM; Biomol) to 6 l Escherichia coli cultures at OD 600 = 0.7-0.9. After 2 h, cells were harvested by centrifugation (3000g, 277 K, 15 min) and stored at 253 K. Cell pellets were resuspended in 50 ml 50 mM NaH 2 PO 4 , 300 mM NaCl, 10 mM imidazole, pH 8.0, and the cells were lysed by sonication. After centrifugation (10 000g, 277 K, 30 min), the supernatant was mixed with 3.6 ml of a 50%(v/v) slurry of Ni-NTA resin (Qiagen) and incubated for 1 h at 277 K. The suspension was transferred to an empty propylene column (Qiagen) and the purification continued at room temperature. The column was washed with 200 ml 50 mM NaH 2 PO 4 , 300 mM NaCl, 20 mM imidazole, pH 8.0, followed by a high-salt washing step with 200 ml 50 mM NaH 2 PO 4 , 2 M NaCl, 50 mM imidazole, pH 8.0, and subsequently washed again with 100 ml 50 mM NaH 2 PO 4 , 300 mM NaCl, 20 mM imidazole, pH 8.0. Bound protein was eluted with 50 mM NaH 2 PO 4 , 300 mM NaCl, 250 mM imidazole, pH 8.0. After SDS-PAGE analysis, fractions containing PbICP-C were pooled and concentrated to 6 mg ml À1 and the buffer was exchanged to 500 mM NaCl, 20 mM Tris, pH 7.5 using centrifugal concentrators (Sartorius). Purified PbICP-C was stored at 277 K.
Inactive mature FP-2 was recombinantly produced and purified in E. coli Origami (DE3) (Novagen). Cells were transformed with the corresponding plasmid and a 4 l culture was grown at 310 K to OD 600 = 0.6. Expression was induced by the addition of IPTG to a final concentration of 0.5 mM. After 4 h incubation, cells were harvested by centrifugation (5000g, 277 K, 15 min) and stored at 253 K. Cell pellets were resuspended in 40 ml 50 mM Tris, 1 mM EDTA, pH 7.5, and lysed by sonication. As FP-2 was produced as inclusion bodies, the supernatant was removed after centrifugation (27 000g, 277 K, 30 min). Protein purity was improved by washing the inclusion bodies twice with 20 ml buffer A (2 M urea, 2.5% Triton X-100, 20 mM Tris, pH 8.0) and twice with 20 ml buffer B (20% sucrose, 20 mM Tris, pH 8.0). Inclusion bodies were resuspended by sonication and pelleted by centrifugation (27 000g, 277 K, 30 min) after each washing step. To remove DNA, the pellet was resuspended in 5 ml buffer B containing 125 units of Benzonase (Sigma) and 10 mM MgCl 2 and stirred overnight at 277 K. 25 ml buffer B was added and the inclusion bodies were pelleted (27 000g, 277 K, 30 min) before solubilization in 15 ml denaturing buffer (8 M urea, 1 M imidazole, 20 mM Tris, pH 8.0). After 120 min incubation at room temperature, insoluble material was removed by centrifugation (27 000g, 277 K, 30 min) and FP-2 was refolded by rapid dilution (1:50) in refolding buffer (25 mM CAPS, 20% sucrose, 250 mM larginine, 1 mM EDTA, 1 mM reduced glutathione, 0.5 mM glutathione disulfide, pH 9.5). After incubation at 277 K for 20 h, the pH was adjusted to 7.5 by the addition of acetic acid and precipitated protein was removed by filtration (0. protein solution was reduced to 40 ml using a 400 ml stirred ultrafiltration cell (Amicon) and it was dialysed overnight against buffer C (50 mM NaCl, 20 mM Tris, pH 7.5, 277 K), loaded onto a 5 ml HiTrap Q HP anion-exchange column (GE Healthcare) and eluted with a linear gradient of 50 mM to 1 M NaCl at room temperature. After SDS-PAGE analysis, fractions containing FP-2 were pooled, concentrated to 2 mg ml À1 using centrifugal concentrators (Sartorius) and stored at 277 K.
Purified proteins were analysed by size-exclusion chromatography (SEC) at room temperature using a Superdex 75 column (10 Â 300 mm; GE Healthcare) equilibrated with buffer D (500 mM NaCl, 20 mM Tris, pH 7.5). The elution profiles (280 nm) of PbICP-C and FP-2 showed single symmetric peaks at elution volumes indicating that both proteins exist as monomers in solution (PbICP-C, 11.75 ml, 23.6 kDa; FP-2, 10.77 ml, 36.9 kDa; Fig. 1a ). To allow the formation of protease-inhibitor complexes, PbICP-C and FP-2 were mixed to final concentrations of 1 mg ml À1 each in buffer D and incubated overnight at 277 K. The SEC elution profile of the sample showed a peak at 11.8 ml (23.1 kDa) and a higher molecular-weight peak at 10.13 ml (49.3 kDa; Fig. 1a ). SDS-PAGE analysis confirmed that the higher molecular-weight species consisted of PbICP-C and FP-2 in a stoichiometric ratio, indicating the formation of a 1:1 complex, whereas the lower molecular-weight species originated from excess free PbICP-C (Fig. 1b) . For preparative isolation of the PbICP-C-FP-2 complex, a Superdex 75 column (16 Â 600 mm; GE Healthcare) at room temperature was used; fractions containing the complex were pooled, concentrated to 2 mg ml À1 using centrifugal concentrators (Sartorius) and stored at 277 K. The isolated complex was highly stable even after several months of storage as confirmed by SDS-PAGE and analytical SEC. initially be obtained from different crystallization conditions, even after extensive optimization none of these crystals diffracted X-rays beyond 6 Å resolution using synchrotron-radiation sources ( Figs. 2a-2c) . Interestingly, crystals grown in the presence of Cd 2+ showed greatly improved diffraction properties. Positive effects of Cd 2+ ions on the crystallization of proteins have been reported previously (Trakhanov et al., 1998; Trakhanov & Quiocho, 1995) . In many cases, Cd 2+ -mediated interactions stabilize intermolecular contacts of adjacent molecules in the crystal lattice (Trakhanov et al., 1998) . The best crystals of the PbICP-C-FP-2 complex were obtained using 200 mM sodium acetate, 27.5 mM CdCl 2 and 100 mM MES pH 5.0 as the reservoir solution. Rod-like crystals grew within 2-4 weeks to final dimensions of 0.5 Â 0.05 Â 0.05 mm (Fig. 2d ). Details of samples and crystallization are summarized in Table 1. 5. X-ray data collection and preliminary X-ray analysis X-ray diffraction data for several crystal forms from different crystallization conditions were collected using synchrotron radiation on beamline BL14.1, BESSY (Berlin, Germany), on beamline X13 (University of Hamburg-University of Lü beck-EMBL) at the DORIS storage ring, DESY (Hamburg, Germany) and on beamline I911, MAX-lab (Lund, Sweden). Diffraction data were processed, reduced and scaled with MOSFLM (Leslie, 1992) and SCALA (Evans, 2006) . The best data set was collected to a resolution of 2.6 Å at 100 K from a single crystal at BESSY using a MAR mosaic 225 mm X-ray diffraction pattern at a resolution of 2.6 Å collected with 0.5 oscillation per image on beamline BL14.1 at BESSY (Berlin, Germany); circles indicate resolution shells. CCD detector (Fig. 3) . The crystals belonged to space group P4 3 , with unit-cell parameters a = b = 71.15, c = 120.09 Å . Data-collection statistics are given in Table 2 . The asymmetric unit contained one PbICP-C-FP-2 complex, corresponding to a Matthews coefficient (Matthews, 1968 ) of 3.16 Å 3 Da À1 and an estimated solvent content of 61%. Inspection of the asymmetric unit after molecular replacement [Phaser Z score of 19.5 (Storoni et al., 2004) ; R = 0.335, R free = 0.373 after initial refinement with REFMAC (Murshudov et al., 2011) ] using FP-2 as a search model (PDB entry 2ghu, chain A, residues 1-241; Hogg et al., 2006) showed additional electron density that could be unambiguously attributed to a PbICP-C molecule. Full structure determination, refinement and analysis of the PbICP-C-FP-2 complex has been reported elsewhere (Hansen et al., 2011) .
Crystallization
APPENDIX A Amino-acid sequences of crystallized components A1. Amino-acid sequence of PbICP-C
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